AYTU BioPharma
AYTU
22 hedge funds and large institutions have $5.03M invested in AYTU BioPharma in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 2 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 6
8% more capital invested
Capital invested by funds: $4.66M → $5.03M (+$372K)
0% more funds holding
Funds holding: 22 → 22 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
13.85% less ownership
Funds ownership: 45.64% → 31.79% (-14%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$45.5K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$39.3K |
| 3 |
Goldman Sachs
New York
|
+$38.2K |
| 4 |
Renaissance Technologies
New York
|
+$22.6K |
| 5 |
JP Morgan Chase
New York
|
+$12.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$21.8K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$10.8K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$9.56K |
| 4 |
BlackRock
New York
|
-$3.49K |
| 5 |
IA
IFP Advisors
Tampa,
Florida
|
-$297 |
AYTU Hedge Fund Activity: Q4 2023 in Review
22 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in AYTU BioPharma (AYTU) for Q4 2023, worth a combined $5.03M — up 8% from $4.66M a quarter earlier.
Fund positioning in AYTU was balanced in Q4 2023: 2 funds opened new positions, 2 closed out, 8 added to existing stakes and 6 trimmed.
The largest buyer was Geode Capital Management, adding an estimated $45.5K. The largest seller was Acadian Asset Management, cutting an estimated $21.8K.
- 22 institutional investors held AYTU BioPharma (AYTU) as of Q4 2023, unchanged from Q3 2023.
- Funds reported $5.03M of AYTU BioPharma stock for Q4 2023, up 8% quarter-over-quarter.
- 2 funds opened new AYTU BioPharma positions in Q4 2023 and 2 closed out, a net change of 0 holders.
- The largest AYTU BioPharma buyer in Q4 2023 was Geode Capital Management, an estimated $45.5K added.
- The largest AYTU BioPharma seller in Q4 2023 was Acadian Asset Management, an estimated $21.8K sold.
Based on aggregated 13F filings for Q4 2023.